Ibritumomab Tiuxetan with Yttrium-90

drug-information.ru

|Ibritumomab Tiuxetan with Yttrium-90

Drugs search, click the first letter of a drug name:


| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9  Home

Ibritumomab Tiuxetan with Yttrium-90


Generic Name: Ibritumomab Tiuxetan with Yttrium-90 (ib-ri-TYOO-mo-mab tye-UX-e-tan)
Brand Name: Y-90 Zevalin

Rituximab, a medicine used along with Ibritumomab Tiuxetan with Yttrium-90 , may cause serious, sometimes fatal side effects, such as difficulty breathing, lung problems, heart attack, irregular heartbeats, or shock. If these side effects are going to occur, they usually occur with the first infusion within 30 minutes to 2 hours. Seek immediate medical attention if you develop severe trouble breathing, swelling, dizziness, lightheadedness, irregular heartbeat, or chest pain.

Ibritumomab Tiuxetan with Yttrium-90 causes severe and prolonged blood problems in most patients. Patients who have certain bone marrow problems should not use Ibritumomab Tiuxetan with Yttrium-90 . If you develop unusual bruising or bleeding, fever, chills, sore throat, or other signs of infection, contact your doctor immediately.

Severe and sometimes fatal skin problems have been reported with use of Ibritumomab Tiuxetan with Yttrium-90 . If you experience red, swollen, blistered, or peeling skin, contact your doctor immediately.


Ibritumomab Tiuxetan with Yttrium-90 is used for:

Treating non-Hodgkin lymphoma that has redeveloped or has not responded to other medicines. It is used in combination with rituximab and 2 radioactive materials (In-111 and Y-90).

Ibritumomab is a monoclonal antibody protein. It works by binding to the cells that are involved in non-Hodgkin lymphoma. It is used in combination with 2 different radioactive materials. The first radioactive material (In-111) is attached to confirm that the cells are being reached. The second radioactive material (Y-90) is attached and damages the cells Ibritumomab Tiuxetan with Yttrium-90 binds to, which helps to reduce the number of abnormal cells involved in non-Hodgkin lymphoma.

Do NOT use Ibritumomab Tiuxetan with Yttrium-90 if:

  • you are allergic to any ingredient in Ibritumomab Tiuxetan with Yttrium-90 , murine (mice, rats) proteins, or indium
  • you have bone marrow depression

Contact your doctor or health care provider right away if any of these apply to you.

Before using Ibritumomab Tiuxetan with Yttrium-90 :

Some medical conditions may interact with Ibritumomab Tiuxetan with Yttrium-90 . Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

  • if you are of childbearing age, pregnant, planning to become pregnant, or are breast-feeding
  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement
  • if you have allergies to medicines, foods, or other substances
  • if you have blood disorders, such as low red blood cell counts, low white blood cell counts, or low platelet counts, or failed stem cell collection

Some MEDICINES MAY INTERACT with Ibritumomab Tiuxetan with Yttrium-90 . Tell your health care provider if you are taking any other medicines, especially any of the following:

  • Aspirin, clopidogrel, warfarin, and other medicines that thin the blood may increase the risk of bleeding when used with Ibritumomab Tiuxetan with Yttrium-90

This may not be a complete list of all interactions that may occur. Ask your health care provider if Ibritumomab Tiuxetan with Yttrium-90 may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Ibritumomab Tiuxetan with Yttrium-90 :

Use Ibritumomab Tiuxetan with Yttrium-90 as directed by your doctor. Check the label on the medicine for exact dosing instructions.

  • Ibritumomab Tiuxetan with Yttrium-90 is administered as an injection at your doctor"s office, hospital, or clinic.
  • Ibritumomab is not a radioactive chemical by itself. There is no risk of radioactive exposure with this medication kit until it is combined with In-111 or Y-90; all radioactive handling precautions should be followed at that time. The radioactive medicine will be added to Ibritumomab Tiuxetan with Yttrium-90 by a properly trained medical professional.
  • After being given another medicine (rituximab), ibritumomab in combination with In-111 will be injected into a vein as prescribed by the doctor. Generally, 7 to 9 days later, another rituximab dose is given, followed by Ibritumomab Tiuxetan with Yttrium-90 . The dosage is based on your medical condition, response to therapy, and an established dosing guideline. Consult your doctor for details.
  • If Ibritumomab Tiuxetan with Yttrium-90 contains particles or is discolored, or if the vial is cracked or damaged in any way, do not use it.
  • Keep this product, as well as syringes and needles, out of the reach of children and away from pets. Do not reuse needles, syringes, or other materials. Dispose of properly after use. Ask your doctor or pharmacist to explain local regulations for proper disposal.
  • If you miss a dose of Ibritumomab Tiuxetan with Yttrium-90 or your dose is interrupted, contact your doctor immediately to establish a new dosing schedule.

Ask your health care provider any questions you may have about how to use Ibritumomab Tiuxetan with Yttrium-90 .

Important safety information:

  • Ibritumomab Tiuxetan with Yttrium-90 may cause dizziness. Do not drive, operate machinery, or do anything else that could be dangerous until you know how you react to Ibritumomab Tiuxetan with Yttrium-90 . Using Ibritumomab Tiuxetan with Yttrium-90 alone, with certain other medicines, or with alcohol may lessen your ability to drive or perform other potentially dangerous tasks.
  • Ibritumomab Tiuxetan with Yttrium-90 may reduce the number of clot-forming cells (platelets) in your blood. To prevent bleeding, avoid situations in which bruising or injury may occur. Report any unusual bleeding, bruising, blood in stools, or dark, tarry stools to your doctor.
  • Ibritumomab Tiuxetan with Yttrium-90 may lower your body"s ability to fight infection. Prevent infection by avoiding contact with people with colds or other infections. Notify your doctor of any signs of infection, including fever, sore throat, rash, or chills.
  • Your doctor may prescribe medicines to be taken 30 minutes before Ibritumomab Tiuxetan with Yttrium-90 is given. These medicines may decrease the risk and/or severity of allergic reactions and some side effects. If you experience difficulty breathing; tightness of the chest; or swelling of the eyelids, face, or lips; or if you develop a rash or hives, tell your doctor immediately. Do not take any more doses of Ibritumomab Tiuxetan with Yttrium-90 until your doctor tells you to do so.
  • Check with your doctor before having vaccinations while you are using Ibritumomab Tiuxetan with Yttrium-90 .
  • Carry an identification card at all times that says you are taking this medication.
  • LAB TESTS, including complete blood cell and platelet counts, may be performed to monitor your progress or to check for side effects. Be sure to keep all doctor and lab appointments.
  • Ibritumomab Tiuxetan with Yttrium-90 is not recommended for use in CHILDREN. Safety and effectiveness have not been confirmed.
  • Men receiving Ibritumomab Tiuxetan with Yttrium-90 should use reliable methods of birth control while, and for at least 1 year after, taking Ibritumomab Tiuxetan with Yttrium-90 . Consult your doctor for more details.
  • Women of childbearing age receiving Ibritumomab Tiuxetan with Yttrium-90 should use reliable methods of birth control while, and for at least 1 year after, taking Ibritumomab Tiuxetan with Yttrium-90 . Consult your doctor for more details.
  • PREGNANCY and BREAST-FEEDING: Ibritumomab Tiuxetan with Yttrium-90 has been shown to cause harm to the fetus. If you think that you may be pregnant, contact your doctor immediately. It is unknown if Ibritumomab Tiuxetan with Yttrium-90 is excreted in breast milk. Do not breast-feed while taking Ibritumomab Tiuxetan with Yttrium-90 .

Possible side effects of Ibritumomab Tiuxetan with Yttrium-90 :

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Anxiety; back pain; bloated stomach; bruising; constipation; diarrhea; dizziness; flu-like symptoms (eg, cough, chills, muscle aches); flushing; headache; increased cough; indigestion; itching; joint pain; loss of appetite; nausea; nosebleed; pain; runny nose; sleeplessness; sore throat; stomach pain; stomach upset; sweating; swelling of the hands and feet; throat irritation; vomiting.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); black, bloody, or dark stools; coffee-ground vomit; easy bruising or bleeding; infection (fever, chills, sore throat); hoarseness; interrupted breathing; loss of appetite; mental or mood changes; one-sided weakness; pain (eg, stomach, muscle, back, or joint); persistent sore throat; red, swollen, blistered, or peeling skin; secondary cancer; stroke; swelling of the hands, feet, face; swelling of the lungs; unusual tiredness; unusual weight loss; unusually fast heartbeat; vision problems; weakness.

This is not a complete list of all side effects that may occur. If you have questions or need medical advice about side effects, contact your doctor or health care provider. You may report side effects to the FDA at 1-800-FDA-1088 (1-800-332-1088) or at http://www.fda.gov/medwatch.

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (http://www.aapcc.org/findyour.htm), or emergency room immediately. Symptoms may include blood problems.

Proper storage of Ibritumomab Tiuxetan with Yttrium-90 :

Ibritumomab Tiuxetan with Yttrium-90 is usually handled and stored by a health care provider. If you are using Ibritumomab Tiuxetan with Yttrium-90 at home, store Ibritumomab Tiuxetan with Yttrium-90 as directed by your pharmacist or health care provider. Keep Ibritumomab Tiuxetan with Yttrium-90 out of the reach of children and away from pets.

General information:

  • If you have any questions about Ibritumomab Tiuxetan with Yttrium-90 , please talk with your doctor, pharmacist, or other health care provider.
  • Ibritumomab Tiuxetan with Yttrium-90 is to be used only by the patient for whom it is prescribed. Do not share it with other people.
  • If your symptoms do not improve or if they become worse, check with your doctor.

This information is a summary only. It does not contain all information about Ibritumomab Tiuxetan with Yttrium-90 . If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: November 1, 2006
Database Edition 06.4.1.002
Copyright © 2006 Wolters Kluwer Health, Inc.




Where can I get more information about Ibritumomab Tiuxetan with Yttrium-90 ? We recommend to use www.Drugs.com

Typical mistypes for Ibritumomab Tiuxetan with Yttrium-90
ubritumomab tiuxetan with yttrium-90, jbritumomab tiuxetan with yttrium-90, kbritumomab tiuxetan with yttrium-90, obritumomab tiuxetan with yttrium-90, 9britumomab tiuxetan with yttrium-90, 8britumomab tiuxetan with yttrium-90, ivritumomab tiuxetan with yttrium-90, inritumomab tiuxetan with yttrium-90, ihritumomab tiuxetan with yttrium-90, igritumomab tiuxetan with yttrium-90, ibeitumomab tiuxetan with yttrium-90, ibditumomab tiuxetan with yttrium-90, ibfitumomab tiuxetan with yttrium-90, ibtitumomab tiuxetan with yttrium-90, ib5itumomab tiuxetan with yttrium-90, ib4itumomab tiuxetan with yttrium-90, ibrutumomab tiuxetan with yttrium-90, ibrjtumomab tiuxetan with yttrium-90, ibrktumomab tiuxetan with yttrium-90, ibrotumomab tiuxetan with yttrium-90, ibr9tumomab tiuxetan with yttrium-90, ibr8tumomab tiuxetan with yttrium-90, ibrirumomab tiuxetan with yttrium-90, ibrifumomab tiuxetan with yttrium-90, ibrigumomab tiuxetan with yttrium-90, ibriyumomab tiuxetan with yttrium-90, ibri6umomab tiuxetan with yttrium-90, ibri5umomab tiuxetan with yttrium-90, ibritymomab tiuxetan with yttrium-90, ibrithmomab tiuxetan with yttrium-90, ibritjmomab tiuxetan with yttrium-90, ibritimomab tiuxetan with yttrium-90, ibrit8momab tiuxetan with yttrium-90, ibrit7momab tiuxetan with yttrium-90, ibritunomab tiuxetan with yttrium-90, ibritukomab tiuxetan with yttrium-90, ibritujomab tiuxetan with yttrium-90, ibritumimab tiuxetan with yttrium-90, ibritumkmab tiuxetan with yttrium-90, ibritumlmab tiuxetan with yttrium-90, ibritumpmab tiuxetan with yttrium-90, ibritum0mab tiuxetan with yttrium-90, ibritum9mab tiuxetan with yttrium-90, ibritumonab tiuxetan with yttrium-90, ibritumokab tiuxetan with yttrium-90, ibritumojab tiuxetan with yttrium-90, ibritumomzb tiuxetan with yttrium-90, ibritumomsb tiuxetan with yttrium-90, ibritumomwb tiuxetan with yttrium-90, ibritumomqb tiuxetan with yttrium-90, ibritumomav tiuxetan with yttrium-90, ibritumoman tiuxetan with yttrium-90, ibritumomah tiuxetan with yttrium-90, ibritumomag tiuxetan with yttrium-90, ibritumomab riuxetan with yttrium-90, ibritumomab fiuxetan with yttrium-90, ibritumomab giuxetan with yttrium-90, ibritumomab yiuxetan with yttrium-90, ibritumomab 6iuxetan with yttrium-90, ibritumomab 5iuxetan with yttrium-90, ibritumomab tuuxetan with yttrium-90, ibritumomab tjuxetan with yttrium-90, ibritumomab tkuxetan with yttrium-90, ibritumomab touxetan with yttrium-90, ibritumomab t9uxetan with yttrium-90, ibritumomab t8uxetan with yttrium-90, ibritumomab tiyxetan with yttrium-90, ibritumomab tihxetan with yttrium-90, ibritumomab tijxetan with yttrium-90, ibritumomab tiixetan with yttrium-90, ibritumomab ti8xetan with yttrium-90, ibritumomab ti7xetan with yttrium-90, ibritumomab tiuzetan with yttrium-90, ibritumomab tiucetan with yttrium-90, ibritumomab tiudetan with yttrium-90, ibritumomab tiusetan with yttrium-90, ibritumomab tiuxwtan with yttrium-90, ibritumomab tiuxstan with yttrium-90, ibritumomab tiuxdtan with yttrium-90, ibritumomab tiuxrtan with yttrium-90, ibritumomab tiux4tan with yttrium-90, ibritumomab tiux3tan with yttrium-90, ibritumomab tiuxeran with yttrium-90, ibritumomab tiuxefan with yttrium-90, ibritumomab tiuxegan with yttrium-90, ibritumomab tiuxeyan with yttrium-90, ibritumomab tiuxe6an with yttrium-90, ibritumomab tiuxe5an with yttrium-90, ibritumomab tiuxetzn with yttrium-90, ibritumomab tiuxetsn with yttrium-90, ibritumomab tiuxetwn with yttrium-90, ibritumomab tiuxetqn with yttrium-90, ibritumomab tiuxetab with yttrium-90, ibritumomab tiuxetam with yttrium-90, ibritumomab tiuxetaj with yttrium-90, ibritumomab tiuxetah with yttrium-90, ibritumomab tiuxetan qith yttrium-90, ibritumomab tiuxetan aith yttrium-90, ibritumomab tiuxetan sith yttrium-90, ibritumomab tiuxetan eith yttrium-90, ibritumomab tiuxetan 3ith yttrium-90, ibritumomab tiuxetan 2ith yttrium-90, ibritumomab tiuxetan wuth yttrium-90, ibritumomab tiuxetan wjth yttrium-90, ibritumomab tiuxetan wkth yttrium-90, ibritumomab tiuxetan woth yttrium-90, ibritumomab tiuxetan w9th yttrium-90, ibritumomab tiuxetan w8th yttrium-90, ibritumomab tiuxetan wirh yttrium-90, ibritumomab tiuxetan wifh yttrium-90, ibritumomab tiuxetan wigh yttrium-90, ibritumomab tiuxetan wiyh yttrium-90, ibritumomab tiuxetan wi6h yttrium-90, ibritumomab tiuxetan wi5h yttrium-90, ibritumomab tiuxetan witg yttrium-90, ibritumomab tiuxetan witb yttrium-90, ibritumomab tiuxetan witn yttrium-90, ibritumomab tiuxetan witj yttrium-90, ibritumomab tiuxetan witu yttrium-90, ibritumomab tiuxetan wity yttrium-90, ibritumomab tiuxetan with tttrium-90, ibritumomab tiuxetan with gttrium-90, ibritumomab tiuxetan with httrium-90, ibritumomab tiuxetan with uttrium-90, ibritumomab tiuxetan with 7ttrium-90, ibritumomab tiuxetan with 6ttrium-90, ibritumomab tiuxetan with yrtrium-90, ibritumomab tiuxetan with yftrium-90, ibritumomab tiuxetan with ygtrium-90, ibritumomab tiuxetan with yytrium-90, ibritumomab tiuxetan with y6trium-90, ibritumomab tiuxetan with y5trium-90, ibritumomab tiuxetan with ytrrium-90, ibritumomab tiuxetan with ytfrium-90, ibritumomab tiuxetan with ytgrium-90, ibritumomab tiuxetan with ytyrium-90, ibritumomab tiuxetan with yt6rium-90, ibritumomab tiuxetan with yt5rium-90, ibritumomab tiuxetan with ytteium-90, ibritumomab tiuxetan with yttdium-90, ibritumomab tiuxetan with yttfium-90, ibritumomab tiuxetan with ytttium-90, ibritumomab tiuxetan with ytt5ium-90, ibritumomab tiuxetan with ytt4ium-90, ibritumomab tiuxetan with yttruum-90, ibritumomab tiuxetan with yttrjum-90, ibritumomab tiuxetan with yttrkum-90, ibritumomab tiuxetan with yttroum-90, ibritumomab tiuxetan with yttr9um-90, ibritumomab tiuxetan with yttr8um-90, ibritumomab tiuxetan with yttriym-90, ibritumomab tiuxetan with yttrihm-90, ibritumomab tiuxetan with yttrijm-90, ibritumomab tiuxetan with yttriim-90, ibritumomab tiuxetan with yttri8m-90, ibritumomab tiuxetan with yttri7m-90, ibritumomab tiuxetan with yttriun-90, ibritumomab tiuxetan with yttriuk-90, ibritumomab tiuxetan with yttriuj-90, ibritumomab tiuxetan with yttrium090, ibritumomab tiuxetan with yttriump90, ibritumomab tiuxetan with yttrium-80, ibritumomab tiuxetan with yttrium-i0, ibritumomab tiuxetan with yttrium-o0, ibritumomab tiuxetan with yttrium-00, ibritumomab tiuxetan with yttrium-99, ibritumomab tiuxetan with yttrium-9o, ibritumomab tiuxetan with yttrium-9p, ibritumomab tiuxetan with yttrium-9-, britumomab tiuxetan with yttrium-90, iritumomab tiuxetan with yttrium-90, ibitumomab tiuxetan with yttrium-90, ibrtumomab tiuxetan with yttrium-90, ibriumomab tiuxetan with yttrium-90, ibritmomab tiuxetan with yttrium-90, ibrituomab tiuxetan with yttrium-90, ibritummab tiuxetan with yttrium-90, ibritumoab tiuxetan with yttrium-90, ibritumomb tiuxetan with yttrium-90, ibritumoma tiuxetan with yttrium-90, ibritumomabtiuxetan with yttrium-90, ibritumomab iuxetan with yttrium-90, ibritumomab tuxetan with yttrium-90, ibritumomab tixetan with yttrium-90, ibritumomab tiuetan with yttrium-90, ibritumomab tiuxtan with yttrium-90, ibritumomab tiuxean with yttrium-90, ibritumomab tiuxetn with yttrium-90, ibritumomab tiuxeta with yttrium-90, ibritumomab tiuxetanwith yttrium-90, ibritumomab tiuxetan ith yttrium-90, ibritumomab tiuxetan wth yttrium-90, ibritumomab tiuxetan wih yttrium-90, ibritumomab tiuxetan wit yttrium-90, ibritumomab tiuxetan withyttrium-90, ibritumomab tiuxetan with ttrium-90, ibritumomab tiuxetan with ytrium-90, ibritumomab tiuxetan with ytrium-90, ibritumomab tiuxetan with yttium-90, ibritumomab tiuxetan with yttrum-90, ibritumomab tiuxetan with yttrim-90, ibritumomab tiuxetan with yttriu-90, ibritumomab tiuxetan with yttrium90, ibritumomab tiuxetan with yttrium-0, ibritumomab tiuxetan with yttrium-9, biritumomab tiuxetan with yttrium-90, irbitumomab tiuxetan with yttrium-90, ibirtumomab tiuxetan with yttrium-90, ibrtiumomab tiuxetan with yttrium-90, ibriutmomab tiuxetan with yttrium-90, ibritmuomab tiuxetan with yttrium-90, ibrituommab tiuxetan with yttrium-90, ibritummoab tiuxetan with yttrium-90, ibritumoamb tiuxetan with yttrium-90, ibritumomba tiuxetan with yttrium-90, ibritumoma btiuxetan with yttrium-90, ibritumomabt iuxetan with yttrium-90, ibritumomab ituxetan with yttrium-90, ibritumomab tuixetan with yttrium-90, ibritumomab tixuetan with yttrium-90, ibritumomab tiuextan with yttrium-90, ibritumomab tiuxtean with yttrium-90, ibritumomab tiuxeatn with yttrium-90, ibritumomab tiuxetna with yttrium-90, ibritumomab tiuxeta nwith yttrium-90, ibritumomab tiuxetanw ith yttrium-90, ibritumomab tiuxetan iwth yttrium-90, ibritumomab tiuxetan wtih yttrium-90, ibritumomab tiuxetan wiht yttrium-90, ibritumomab tiuxetan wit hyttrium-90, ibritumomab tiuxetan withy ttrium-90, ibritumomab tiuxetan with tytrium-90, ibritumomab tiuxetan with ytrtium-90, ibritumomab tiuxetan with yttirum-90, ibritumomab tiuxetan with yttruim-90, ibritumomab tiuxetan with yttrimu-90, ibritumomab tiuxetan with yttriu-m90, ibritumomab tiuxetan with yttrium9-0, ibritumomab tiuxetan with yttrium-09, iibritumomab tiuxetan with yttrium-90, ibbritumomab tiuxetan with yttrium-90, ibrritumomab tiuxetan with yttrium-90, ibriitumomab tiuxetan with yttrium-90, ibrittumomab tiuxetan with yttrium-90, ibrituumomab tiuxetan with yttrium-90, ibritummomab tiuxetan with yttrium-90, ibritumoomab tiuxetan with yttrium-90, ibritumommab tiuxetan with yttrium-90, ibritumomaab tiuxetan with yttrium-90, ibritumomabb tiuxetan with yttrium-90, ibritumomab tiuxetan with yttrium-90, ibritumomab ttiuxetan with yttrium-90, ibritumomab tiiuxetan with yttrium-90, ibritumomab tiuuxetan with yttrium-90, ibritumomab tiuxxetan with yttrium-90, ibritumomab tiuxeetan with yttrium-90, ibritumomab tiuxettan with yttrium-90, ibritumomab tiuxetaan with yttrium-90, ibritumomab tiuxetann with yttrium-90, ibritumomab tiuxetan with yttrium-90, ibritumomab tiuxetan wwith yttrium-90, ibritumomab tiuxetan wiith yttrium-90, ibritumomab tiuxetan witth yttrium-90, ibritumomab tiuxetan withh yttrium-90, ibritumomab tiuxetan with yttrium-90, ibritumomab tiuxetan with yyttrium-90, ibritumomab tiuxetan with ytttrium-90, ibritumomab tiuxetan with ytttrium-90, ibritumomab tiuxetan with yttrrium-90, ibritumomab tiuxetan with yttriium-90, ibritumomab tiuxetan with yttriuum-90, ibritumomab tiuxetan with yttriumm-90, ibritumomab tiuxetan with yttrium--90, ibritumomab tiuxetan with yttrium-990, ibritumomab tiuxetan with yttrium-900, etc.


© Copyright by drug-information.ru 2001-2012. All rights reserved